Other Professional, Scientific, and Technical Services (U.S.) — NAICS 5419

A Histometrics rollup primer for public-market and private investors. This is a NAICS industry group (4-digit level) that rolls up five child industries — 54191, 54192, 54193, 54194, and 54199. Federal figures are our ground-truth dataset (U.S. Census Bureau); market-size and ownership detail are synthesized from the five child primers and labeled where they come from private research or represent the author's judgment rather than fact.

---

1. Overview

The North American Industry Classification System (NAICS — the standard the U.S. statistical agencies use to group businesses) puts five unrelated trades in one drawer labeled 5419, "Other Professional, Scientific, and Technical Services." It is a residual bucket: the professional and technical services that were not important enough, or not similar enough, to get their own named 4-digit group alongside legal (5411), accounting (5412), engineering (5413), or advertising (5418). What ended up here is a genuinely mixed set — animal hospitals, opinion pollsters, portrait and product photographers, court and medical interpreters, and a catch-all of niche experts from marine surveyors to commercial weather forecasters.[1][2]

For an investor, the single most useful fact about this level is that it is not one industry — it is five, and they barely touch. They sell to different customers, on different economics, at very different sizes, and they are owned by very different people. A rollup primer earns its keep by contrasting them, so Section 2 leads with that comparison. Two threads, however, do run through all five and are worth stating up front:

• There is no clean U.S.-listed pure-play in any of the five children. Every route into public markets is indirect — an adjacent ecosystem stock, a licensing platform one code over, a foreign listing, or a private-equity manager that happens to own an operator. The businesses that actually generate the ~$130 billion of revenue here live overwhelmingly in private hands — founder-owned, private-equity-backed, and (in one case) family-owned.[3][4][5][6][7]
• Private equity (PE — investment firms that buy companies using pooled capital and debt) is the consolidation engine in every one of them, though it rolls up different layers in each: the clinics themselves in veterinary, the data giants in marketing research, the "super-agencies" in translation, the school-photo operators in portrait, and founder-owned specialists across the catch-all.[3][4][5][6][7]

---

2. What's inside — the five children and how they differ

This is the heart of the rollup. Each child is a distinct market; the table contrasts them on the axes an investor actually cares about. Shares are of the level's 2022 receipts ($129.6 billion) and its 2023 employment (785,370), so the columns reconcile into Section 3.[1]

How to read the table. Three quick definitions: CR4 is the combined revenue share of the four largest firms (a concentration ratio); HHI is the Herfindahl-Hirschman Index, a 0–10,000 concentration score where U.S. antitrust agencies treat 1,500 as the floor for a "concentrated" market — every reading here is far below that. TIC is testing, inspection, and certification. Tickers are defined where they first appear in Section 4.

The contrast that matters most:

• One child is the whole story on size. Veterinary services alone is ~48% of the level's revenue and ~61% of its jobs — bigger by receipts than the other four combined twice over on the employment side.[1][7] Add the catch-all (54199) and marketing research (54191) and you have ~89% of the money.[1] Photographic and translation are small — about a nickel of every revenue dollar each.
• The children run on different clocks and different customers. Veterinary is a licensed, largely cash-pay health-care business growing with pet ownership; marketing research and photographic-commercial ride cyclical advertising and corporate budgets; translation rides federal civil-rights language mandates; the catch-all rides a bundle of unrelated micro-drivers (inspections, litigation, trade, weather). They do not fall — or rise — in lockstep, which makes the level steadier than most of its parts.
• Concentration is a paradox to be explained, not read off the total (see Section 3).

---

3. How big it is (the level, rolled up)

Federal statistics for the employer side of NAICS 5419, from our ground-truth dataset. These come from two different Census programs and vintages and should not be summed into a single figure:[1]

The rollup reconciles cleanly. The five children sum almost exactly into these totals: receipts ($62.8B + $28.0B + $25.2B + $6.85B + $6.77B) ≈ $129.6B; employees (475,106 + 139,378 + 78,424 + 50,967 + 41,495) = 785,370 exactly; establishments (34,296 + 24,892 + 16,504 + 4,401 + 2,801) = 82,894 exactly; annual payroll (~$25.2B + $12.43B + $8.15B + $2.18B + $1.98B) ≈ $49.9B.[3][4][5][6][7] That internal consistency is worth flagging — this is a genuine aggregate, not an estimate stitched from mismatched sources.

A few level-wide reads:

• This is a well-paid professional workforce — on average. About $2.0 million of receipts per employer firm and ~$63,600 of annual pay per employee (mixing 2022 and 2023 vintages, so treat as a profile, not a ratio).[1] But the average hides a wide spread: marketing research pays roughly $104,000 per head and the catch-all ~$89,000 (expert, credentialed labor), while photographic pays only ~$39,000 (heavy seasonal, part-time picture-day work) and veterinary and translation sit near $53,000.[3][4][5][6][7]
• The concentration paradox. The level's HHI of 54.8 and CR4 of 11.2% are lower than every single child's (the least concentrated child, 54199, still posts HHI 77.5).[1][3] That is not because the level is more competitive — it is an artifact of aggregating five non-overlapping markets. Mars dominates veterinary but holds zero share of translation; LanguageLine leads interpreting but none of vet; NIQ leads measurement but none of the others. Stacking them mechanically dilutes measured concentration. The real competition happens inside each child, several of which are meaningfully more concentrated than the 54.8 headline suggests — translation most of all (HHI 395).[1][5]
• Seasonality washes out at the level. First-quarter payroll is ~24.3% of the annual total — close to an even 25%.[1] Photographic's autumn-heavy school season is a real seasonal signal inside one small child, but it is too small to move the aggregate.[6]

The undercount caveat — and it is large, but uneven. Both federal programs count only businesses with paid employees, and several children lean heavily on people the tables can't see. Photography is roughly two-thirds self-employed; translation is about one-third self-employed and delivers huge volumes through in-house hospital and court staff; the catch-all is thick with solo appraisers, surveyors, and one-person forecasting shops; marketing research has a long tail of independent researchers.[4][5][6][3] The big exception is veterinary, which is mostly an employer industry (clinics have staff), so the level's largest child is also its best-measured one.[7] Our ground-truth file for 5419 contains no nonemployer, in-house, government, profit, or pricing series, so none is invented here — but the true operator count and total activity are materially larger than the ~$129.6 billion employer figure, and the gap is heaviest in the four smaller children, lightest in veterinary. Read the federal number as a floor for the organized, employer slice.

---

4. The investable universe (where value concentrates across the children)

The defining fact bears repeating: there is no U.S.-listed company whose core business is any of these five codes. Where value concentrates — and how you reach it — differs child by child, and that is the map:

• Veterinary (the biggest pool) → ecosystem stocks, because the clinics are private. The ~$62.8 billion of clinic revenue is owned by Mars Veterinary Health (family-owned, the single largest U.S. provider — Banfield/VCA/BluePearl), JAB's NVA/Ethos, and PE platforms (VetCor, Thrive, PetVet, Mission Pet Health).[7] Public-market investors instead buy the businesses around the exam table: diagnostics IDEXX (Nasdaq: IDXX), animal-health pharma Zoetis (NYSE: ZTS) and Elanco (NYSE: ELAN), pet insurance Trupanion (Nasdaq: TRUP), retail-plus-clinics Petco (Nasdaq: WOOF), Chewy (NYSE: CHWY), and Tractor Supply (Nasdaq: TSCO), plus one nano-cap pure-play operator (Inspire Veterinary Partners, Nasdaq: IVP) and the UK's CVS Group (AIM: CVSG) as the closest at-scale listed clinic operator.[7]
• Marketing research → thin foreign and adjacent listings. A small set of listed pure-plays (NIQ on the NYSE, Ipsos in Paris, YouGov in London, Comscore on Nasdaq) sits beside diversified adjacent names (Gartner, IQVIA, DoubleVerify); the most valuable assets — Nielsen, Kantar, Circana, Dynata, Qualtrics — are PE-owned and private.[4]
• Photographic → licensing platforms one code over. The production trade is too fragmented to have a champion, so exposure comes from the image-licensing platforms that distribute what studios shoot — Getty Images (NYSE: GETY), Shutterstock (NYSE: SSTK), and Adobe (Nasdaq: ADBE) — which are a different NAICS code and are the closest proxy for commercial photography's economy, not its production code.[6] The portrait leaders (Lifetouch, Jostens, Herff Jones) are reached only faintly through their PE owners Apollo (NYSE: APO) and KKR (NYSE: KKR).[6]
• Translation → a couple of foreign listings and an IPO to watch. The closest near-pure-play is RWS Holdings (London: RWS); Teleperformance (Paris: TEP) owns the #1 interpreting brand LanguageLine inside a much larger outsourcing group; the potential DeepL IPO is the most-watched new listing. Scale (TransPerfect, Lionbridge, Welocalize, Acolad) is founder- and PE-owned.[5]
• The catch-all → small-cap and diversified proxies. Industrial inspection MISTRAS Group and Team, Inc. are the most direct listed exposure; diversified TIC groups (Intertek, Bureau Veritas, SGS, Eurofins, UL Solutions, mostly listed abroad) touch it as a slice; Spire Global is a listed commercial-weather play.[3]

The through-line for public-market investors: you cannot buy this industry group directly. Every listed name is a proxy — an ecosystem supplier, a licensing platform, a foreign LSP (language-service provider), or a PE manager — so each must be judged on its actual business mix, not on the NAICS label. The real ownership is private, which is why Section 10 gives private routes equal weight.

---

5. How the money works

Four of the five children are asset-light, people-based businesses: they sell expert time, reports, inspections, and subscriptions, carry little inventory, and spend little on capital. Returns are set by three levers that recur across them — billable utilization (how much of the workforce's time is booked and paid), the share of recurring revenue (subscriptions, monitoring, multi-year contracts), and credentials (an accredited inspection body, a court-recognized interpreter, an owner of a proprietary measurement dataset), which confer the pricing power that separates a commodity vendor from a durable franchise.[3][4][5][6] The concrete fee models differ — per word or per minute (translation), per report or per unit inspected (appraisal, marine survey, pipeline), day-rate field work (commercial photography), and syndicated-data subscriptions (measurement) — but the economic question is the same: how much of the revenue is sticky and defensible versus one-off and price-competed.

Veterinary is the exception, and it is nearly half the level, so it deserves its own paragraph. A vet clinic is a largely cash-pay medical business with two streams: professional services (exams, surgery, dentistry, diagnostics) and product sales (medications, therapeutic diets), the latter roughly 10–26% of revenue.[7] Because pet insurance covers only about 4% of U.S. pets and reimburses the owner rather than negotiating network rates, clinics set their own prices with no third-party payer clawing them back — a structural advantage human health care lacks.[7] The corporate owners make money through the roll-up: buy practices at a multiple of EBITDA (earnings before interest, taxes, depreciation, and amortization), finance largely with debt, and create value through multiple arbitrage, operating synergy, and organic growth.[7]

Across the whole level, the useful operating metrics — utilization, recurring-revenue share, renewal rates, contributor/royalty economics, same-clinic growth — are company-specific and not in the federal data, so they must be tested one operator at a time.

---

6. What drives demand

Demand is not one thing here; it is five loosely correlated engines, which is precisely why the aggregate is steadier than its parts:

• Veterinary — structural, non-cyclical growth. Roughly seven in ten U.S. households own a pet; "humanization" pushes owners toward advanced care; pets are aging; and vet care is relatively recession-resistant (largely discretionary but emotionally non-negotiable). The near-term wrinkle is an affordability ceiling — prices have outrun inflation and visit volumes have softened.[7]
• Marketing research — cyclical, tied to marketing accountability. Demand rises with new-product launches, brand competition, and media fragmentation across streaming and connected TV, and with the shift to first-party data as tracking cookies disappear. It is discretionary and among the first budgets cut in a downturn, though recurring measurement contracts are more resilient.[4]
• Translation — regulatory and demographic, unusually durable. About 22% of U.S. residents speak a language other than English at home (~25 million with limited English proficiency), and federal civil-rights law (Title VI, Section 1557 of the Affordable Care Act, the Americans with Disabilities Act) mandates language access in health care, courts, and public services.[5]
• Photographic — split between two cycles. Portrait rides consumer life events (births, school picture day, weddings); commercial rides business ad, e-commerce, and real-estate budgets. Neither shares a calendar with the other.[6]
• The catch-all — a bundle of micro-drivers. Mandated inspections and compliance, aging infrastructure and industrial capex, global trade volumes, litigation and estates, weather sensitivity, and countercyclical consumer financial stress (credit counseling) each move a different slice.[3]

The shared counter-current is AI (artificial intelligence — software that generates or simulates human work). It cuts both ways in four of the five children: deflating commodity written translation, generic headshots and stock imagery, and standardized valuation/research work, while adding demand for higher-throughput delivery, model validation, and training-data licensing.[3][4][5][6] Veterinary is the AI-insulated child — hands-on animal medicine cannot be automated, though diagnostics and telemedicine are being reshaped at the edges.[7]

---

7. Regulation

Regulation is wildly uneven across the level — from one of its most-licensed industries to some of its least — and this dispersion is itself an investment consideration:

• Veterinary is heavily regulated, primarily at the state level (practice acts and licensing boards), with federal overlays. The load-bearing items for investors are Corporate Practice of Veterinary Medicine (CPOM) rules that dictate how PE consolidators may legally structure ownership, the Veterinarian-Client-Patient Relationship (VCPR) requirement that limits telemedicine, DEA registration for controlled substances, and active Federal Trade Commission antitrust attention to vet-clinic roll-ups.[7]
• Translation is regulated indirectly — as a demand engine. The statutory backbone (Title VI, ACA Section 1557, the ADA) manufactures the market; the swing factor to watch is Executive Order 14224 (March 2025), which designated English the official U.S. language — a bounded headwind to federally driven demand that does not repeal the underlying statutes.[5]
• The other three are lightly regulated trades that lean on self-governance. Marketing research has no licensing regime and touches privacy law (state privacy acts, Europe's GDPR, FTC authority, telephone-survey rules); photographic is a lightly licensed craft sitting on a serious body of intellectual-property law (copyright, model/property releases, FAA Part 107 for drone work, and the live AI-copyright litigation front); the catch-all is mostly accreditation-based (ISO/IEC 17020 for inspection bodies, USPAP for appraisers) where a public mandate creates demand and its absence keeps a niche crowded.[3][4][6]

The pattern: where a public authority mandates the service (vet licensing, language access, mandated inspection), it both constrains supply and manufactures demand; where it doesn't, low barriers keep the field fragmented — which explains much of the ownership and concentration map above.

---

8. Consolidation

PE roll-up is the shared plot across all five children — but it plays out at a different layer in each, and that is the distinctive read.

• Veterinary — the marquee roll-up, at the operating layer itself. National concentration looks modest (CR4 22.4%), but that understates a fast-moving, locally fought consolidation: corporate ownership of general practices has climbed from ~8% around 2011 to an estimated quarter-to-half, and to a clear majority in specialty/emergency care, led by Mars, JAB's NVA/Ethos, and PE platforms.[7] This is where the sector's real merger energy — and its antitrust scrutiny — sits.
• Marketing research — roll-up at the top, of the data giants. The fragmented base stays fragmented; the consolidation is among the "currency" dataset owners: Nielsen taken private, NielsenIQ+GfK floated as NIQ, IRI+NPD merged into Circana, Kantar majority-owned by Bain, Qualtrics taken private by Silver Lake.[4]
• Translation — roll-up into "super-agencies." H.I.G. holds Lionbridge, TP bought LanguageLine, EQT took Keywords private — the frontier shifting from "who has the most linguists" to technology plus regulated, interpreting-heavy work AI can't safely automate.[5]
• Photographic — roll-up on the portrait top; M&A drama one code over in commercial. The organized school-photo business is PE-assembled (Apollo/Lifetouch, KKR/Atlas), while the atomistic commercial-production layer won't consolidate at all — so its money and merger activity migrated to the licensing platforms, where the ~$3.7 billion Getty-Shutterstock "merger of equals" was announced in January 2025 and terminated in July 2026 after antitrust friction.[6]
• The catch-all — classic buy-and-build. The broader TIC sector saw 280-plus M&A deals in 2025, PE's share of deal flow rising from ~22% to ~36% over a decade, on the math of buying founder-owned specialists near 6–8× EBITDA and exiting at 14–16×.[3]

The through-line: this industry group is a consolidation theme, not a consolidation event — five parallel roll-ups, each buying a different layer, none yet producing a marquee U.S.-listed operator. The awaited catalyst is a public listing of one of the large private platforms (most plausibly a veterinary group), which would give public investors their first direct, at-scale ownership of any operator in the entire level.

---

9. Risks

Ordered from the shared and structural to the child-specific:

• No direct public ownership (level-wide). Because every listed name is a proxy, public-market investors carry mismatch risk — the stock's fortunes depend on an adjacent business (diagnostics, licensing, outsourcing) that may diverge from the underlying trade.
• AI substitution (shared by four of five). Generative AI presses on commodity translation, generic photography and stock imagery, and standardized valuation/research work — a net downward force on low-end pricing, offset only where operators turn it into throughput or lean into work it can't safely do.[3][4][5][6]
• PE leverage (shared, most acute in veterinary and translation). The roll-up model runs on debt; softer volumes and higher rates put refinancing pressure on the most-levered platforms, with private-credit exposure to veterinary roll-ups already under scrutiny.[7]
• Cyclicality, from unrelated cycles. Marketing research and commercial photography track discretionary ad and corporate budgets; the catch-all tracks industrial capex, trade, and litigation; veterinary tracks consumer pet spend against a price ceiling. The lack of correlation is a mild diversification benefit at the level, but each child carries its own downturn risk.[3][4][6][7]
• Regulatory/antitrust friction on the roll-ups (FTC attention to vet consolidation; the blocked Getty-Shutterstock deal) and regulatory reversal of demand (EO 14224 on federal language spending).[5][6][7]
• Structural fragmentation and low barriers in marketing research, photographic, and the catch-all — limited pricing power, easy entry, key-person risk (value walks out the door at night).[3][4][6]
• Measurement risk (level-wide). The employer statistics materially undercount the nonemployer tail (heaviest in photographic, translation, and the catch-all), so any read of "the industry" from the federal tables understates it.[1]

---

10. How to invest, and the outlook

Public routes — all indirect, each child pointing somewhere different. There is no way to buy NAICS 5419 as such; the honest routes are:

• Veterinary → an ecosystem basket: diagnostics IDXX, pharma ZTS/ELAN, insurance TRUP, retail-clinics WOOF/CHWY/TSCO, plus CVSG (UK) as the closest at-scale operator and IVP as a nano-cap pure-play — treated as different exposures, not as clinics.[7]
• Marketing research → listed pure-plays NIQ, Ipsos, YouGov, Comscore and adjacents Gartner, IQVIA.[4]
• Photographic → licensing/software GETY, SSTK, ADBE (now confirmed to be staying separate) and, faintly, PE managers APO/KKR for portrait.[6]
• Translation → RWS and Teleperformance (for LanguageLine), with a watch on a possible DeepL IPO.[5]
• The catch-all → MISTRAS, Team, diversified TIC (Intertek, Bureau Veritas, SGS, Eurofins, UL), and Spire for weather.[3]

In every case, judge the company on its actual mix — utilization, recurring-revenue share, contract renewal, AI exposure and rights quality, customer concentration, net debt, and acquisition discipline — before its share price, dividend yield, or valuation multiple.

Private routes — where the industry actually lives. For four of the five children (all but the exceptionally capital-heavy nothing here), the operators are small, financeable, private businesses. The playbook: back or run a veterinary practice or PE platform (and vet real estate); search-fund an acquisition of a founder-owned appraisal, inspection, translation, or research firm; build a buy-and-build in a defined niche on the 6–8×-in / 14–16×-out consolidation math; or lend to the sponsor-owned platforms as a private-credit / business-development-company investor.[3][4][5][7]

Outlook (author's judgment, not fact — our federal data carry no forecast). The level should grow at a low-to-mid single-digit nominal pace, but the aggregate hides five diverging stories. Veterinary — nearly half the level — stays the durable, structurally growing, cash-pay core, its main near-term risk an affordability ceiling and leveraged balance sheets; it is also the likeliest source of the first at-scale public operator. Marketing research and translation bifurcate the same way — recurring, specialized, AI-resistant work stays durable while commodity survey and per-word work deflates. Photographic and commercial imagery barbell into an automated commodity middle and a resilient human-made premium, with the money sitting in licensing platforms. The catch-all stays a steady, fragmented, consolidating field that won't produce a marquee stock but rewards disciplined roll-ups. Across the whole group, expect continued PE consolidation in every child, a persistent private/independent tail, no clean public pure-play, and AI as the single variable that cuts both ways — sharpest in translation and photography, gentlest in the veterinary business that anchors the level.

---

Sources

1. Histometrics ground-truth federal dataset — NAICS 5419 (U.S. Census Bureau, 2022 Economic Census concentration table and 2023 County Business Patterns). Receipts $129,599,270 thousand; firms 64,771; establishments 82,894; employees 785,370; annual payroll $49,923,400 thousand; Q1 payroll $12,144,063 thousand; CR4 11.2% / CR8 15.7% / CR20 23.5% / CR50 32.1%; HHI 54.8.
2. U.S. Census Bureau. "2022 NAICS Structure — Industry Group 5419, Other Professional, Scientific, and Technical Services, and its child industries 54191, 54192, 54193, 54194, 54199." https://www.census.gov/naics/?year=2022
3. Histometrics child primer — NAICS 54199, All Other Professional, Scientific, and Technical Services (primer-54199-DRAFT.md), which carries the full investable universe, fee models, demand drivers, regulation, TIC-consolidation math, and risks summarized here.
4. Histometrics child primer — NAICS 54191, Marketing Research and Public Opinion Polling (primer-54191-DRAFT.md), and through it the 541910 leaf primer; source of the marketing-research figures, ownership map (Nielsen/Kantar/Circana/Dynata/Qualtrics; NIQ/Ipsos/YouGov/Comscore), and ESOMAR market sizing.
5. Histometrics child primer — NAICS 54193, Translation and Interpretation Services (primer-54193-DRAFT.md), and through it the 541930 leaf primer; source of the language-services figures, ownership map (RWS, Teleperformance/LanguageLine, TransPerfect, Lionbridge, Welocalize, DeepL), and the EO 14224 regulatory point.
6. Histometrics child primer — NAICS 54192, Photographic Services (primer-54192-DRAFT.md), covering children 541921 (portrait) and 541922 (commercial); source of the photographic figures, ownership map (Apollo/Lifetouch, KKR; Getty/Shutterstock/Adobe), and the terminated Getty-Shutterstock merger.
7. Histometrics child primer — NAICS 54194, Veterinary Services (primer-54194-DRAFT.md), and through it the 541940 leaf primer; source of the veterinary figures, ownership map (Mars, JAB/NVA/Ethos, VetCor/Thrive/PetVet), ecosystem stocks (IDXX, ZTS, ELAN, TRUP, WOOF, CHWY, TSCO, IVP, CVSG), and CPOM/VCPR regulation.